Semaglutide vs Tirzepatide
Semaglutide and Tirzepatide are both incretin-based compounds studied in metabolic research, and both have been investigated as once-weekly subcutaneous agents. Semaglutide is a long-acting GLP-1 receptor agonist whose structural modifications extend its half-life. Research has examined its role in glucose-dependent insulin signaling, gastric emptying, satiety pathways, and weight loss in obesity without diabetes. Tirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors, and research asks whether adding the GIP component differs from GLP-1 agonism alone. Its phase 3 program has examined glycemic control in type 2 diabetes, weight reduction and maintenance in adults with obesity, and a head-to-head comparison with semaglutide in SURPASS-2.
Key differences. In plain words.
- 01
Semaglutide is studied at a single target, the GLP-1 receptor, while Tirzepatide is studied at both the GLP-1 and GIP receptors.
- 02
A semaglutide product, Wegovy, has been described in the literature as a weight loss drug for chronic weight management, whereas Tirzepatide is characterized by multiple randomized phase 3 trials, including SURPASS-1, SURPASS-2 and SURMOUNT-4.
- 03
Semaglutide research has placed particular emphasis on the structural modifications that extend its half-life and on its clinical pharmacokinetics.
- 04
Tirzepatide research extends into phase 2 work in metabolic dysfunction-associated steatohepatitis with liver fibrosis and a cardiovascular outcomes trial against dulaglutide, while semaglutide has been examined for heart failure with preserved ejection fraction in observational research.
- 05
Published safety topics differ: semaglutide research has examined nonarteritic anterior ischemic optic neuropathy risk and effects on lean mass, while Tirzepatide cardiovascular safety is being assessed in the SURPASS-CVOT trial and its long-term safety outside controlled trials is not well characterized.
Side by side. From the research.
Studied ranges describe what published research protocols have used. They are not instructions or recommendations. Products are sold for research purposes only; each order ships with a protocol guide for the specific product.
Mechanism
How it is thought to work
Semaglutide
Research describes semaglutide as an incretin mimetic with structural modifications that extend its half-life, studied for both peripheral glucose handling and central appetite signaling.
Incretin Pathway
Studied at the GLP-1 receptor for glucose-dependent insulin release rather than unconditional stimulation.
Gastric Emptying
Explored for slowing the rate at which the stomach empties, associated with prolonged fullness.
How it is thought to work
Tirzepatide
Research investigates tirzepatide across both incretin receptors, studied for combined effects on insulin signaling, gastric emptying, and satiety.
Dual Incretin
Studied at both GIP and GLP-1 receptors, the GIP component distinguishing it from single agonists.
Metabolic Signaling
Explored for effects across glucose handling and appetite regulation together.
Ask about Semaglutide and Tirzepatide
Plain answers from our library and the cited studies.
AI answers can be wrong. Research use only.

